Vir Biotechnology Inc said on Tuesday it had received $55 million in funding from the U.S. government to support its influenza-focused antibody drug that is expected to enter mid-stage trials this year.
The multi-year contract with Biomedical Advanced Research and Development Authority (BARDA) also allows for potential investment of up to $1 billion by the government for developing candidates against emerging infectious disease, including influenza.
The company developed a COVID-19 antibody drug, sotrovimab, along with GSK plc during the pandemic. The BARDA contract will help prepare against future pandemics, Vir Chief Executive Officer George Scangos said.
https://finance.yahoo.com/news/vir-biotech-gets-u-funding-120002522.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.